Immunovant prioritizes IMVT-1402 over batoclimab in FcRn competition

Immunovant has announced a strategic shift in its clinical development priorities, placing a stronger emphasis on its next-generation FcRn inhibitor, IMVT-1402, over the previously highlighted batoclimab. This transition entails a delay in the clinical progress of batoclimab as the company focuses on the promising potential of IMVT-1402 for a variety of autoantibody-driven conditions.

In a recent corporate update, Immunovant disclosed plans to initiate four to five potentially registrational studies for IMVT-1402 by the end of March 2025. These studies will cover key therapeutic areas, including endocrinology and neurology. The company has ambitious goals, aiming to expand this number to a total of 10 indications by the end of 2026.

CEO Pete Salzmann expressed enthusiasm about the evolving immunology market, highlighting the potential of the anti-FcRn mechanism to become a leading therapeutic class for a wide array of autoantibody-driven diseases. Salzmann emphasized the unique advantages of IMVT-1402, suggesting that it possesses a combination of potentially best-in-class features that have not been observed with any other FcRn inhibitors.

In summary, Immunovant's realignment of its clinical development focus underscores its confidence in the future of IMVT-1402 and its potential to revolutionize treatment across multiple therapeutic areas.